SERS Sensor Based on CHA Reaction for EGFR Mutation Typing in Advanced Lung Cancer
Not yet recruiting
- Conditions
- Lung Cancer in Normal and Malignant Tumors
- First Posted Date
- 2025-03-25
- Last Posted Date
- 2025-03-31
- Lead Sponsor
- Fuzhou General Hospital
- Target Recruit Count
- 400
- Registration Number
- NCT06772376
SERS-Based Serum Molecular Spectral Screening for Hematogenous Metastasis
Not yet recruiting
- Conditions
- Lung Cancers
- First Posted Date
- 2025-03-25
- Last Posted Date
- 2025-03-31
- Lead Sponsor
- Fuzhou General Hospital
- Target Recruit Count
- 200
- Registration Number
- NCT06772363
- Locations
- 🇨🇳
Raman detector, Fuzhou, Fujian, China
SERS-Based Serum Molecular Spectral Screening for Lung Cancer Type
Not yet recruiting
- Conditions
- Lung Cancer, Non-Small CellLung Cancer Small Cell Lung Cancer (SCLC)
- First Posted Date
- 2025-03-25
- Last Posted Date
- 2025-03-31
- Lead Sponsor
- Fuzhou General Hospital
- Target Recruit Count
- 223
- Registration Number
- NCT06775002
SERS-Based Serum Molecular Spectral Detection of Invasive Lung Cancer
Not yet recruiting
- Conditions
- Lung Cancer Patients
- First Posted Date
- 2025-03-25
- Last Posted Date
- 2025-03-31
- Lead Sponsor
- Fuzhou General Hospital
- Target Recruit Count
- 200
- Registration Number
- NCT06775015
- Locations
- 🇨🇳
The 900th Hospital of the Joint Logistic Support Force, PLA, Fuzhou, Fujian, China
SERS-Based Serum Molecular Spectral Screening for Benign and Malignant Pulmonary Proliferative Nodules
Not yet recruiting
- Conditions
- Lung Cancer in Normal and Malignant Tumors
- First Posted Date
- 2025-03-25
- Last Posted Date
- 2025-03-31
- Lead Sponsor
- Fuzhou General Hospital
- Target Recruit Count
- 200
- Registration Number
- NCT06775587
- Locations
- 🇨🇳
Raman detector, Fuzhou, Fujian, China
QYJD Compound Preparation Promotes Rapid Postoperative Recovery in Early-stage NSCLC Patients by Regulating Tissue Microecology: a Prospective, Randomized Controlled, Open-label, Phase I Clinical Study With Predefined Future Exploration
Phase 1
Completed
- Conditions
- NSCLC
- Interventions
- Drug: QYJD Compound Preparation
- First Posted Date
- 2025-01-09
- Last Posted Date
- 2025-01-09
- Lead Sponsor
- Fuzhou General Hospital
- Target Recruit Count
- 15
- Registration Number
- NCT06766565
- Locations
- 🇨🇳
Zongyang Yu, Fujian, Fuzhou, China
Defining COVID-19 Infection Severity on Presentation to Hospital
Recruiting
- Conditions
- InfectionsMoralityCOVID-19Death, Assisted
- Interventions
- Diagnostic Test: Supportive treatment (BSC)Diagnostic Test: Medical observationDiagnostic Test: Intensive care management
- First Posted Date
- 2023-01-10
- Last Posted Date
- 2023-01-10
- Lead Sponsor
- Fuzhou General Hospital
- Target Recruit Count
- 3000
- Registration Number
- NCT05677789
- Locations
- 🇨🇳
The 900th Hospital of the Joint Logistic Support Force, PLA, Fuzhou, Fujian, China
The Efficacy and Safety of Azovudine in the Treatment of COVID-19
Recruiting
- Conditions
- COVID-19InfectionsMoralityDeath, Assisted
- Interventions
- Drug: Azorubine
- First Posted Date
- 2023-01-09
- Last Posted Date
- 2023-01-10
- Lead Sponsor
- Fuzhou General Hospital
- Target Recruit Count
- 500
- Registration Number
- NCT05675761
- Locations
- 🇨🇳
The 900th Hospital of the Joint Logistic Support Force, PLA, Fuzhou, Fujian, China
Induction Tislelizumab Combined With Chemotherapy Followed by Definitive Chemoradiotherapy in the Treatment of Locally Unresectable Esophageal Squamous Cell Carcinoma
Phase 2
Recruiting
- Conditions
- Immunotherapy Esophagus Cancer
- Interventions
- First Posted Date
- 2022-08-25
- Last Posted Date
- 2024-02-07
- Lead Sponsor
- Fuzhou General Hospital
- Target Recruit Count
- 93
- Registration Number
- NCT05515315
- Locations
- 🇨🇳
Ye zai sheng, Fuzhou, Fujian, China
ctDNA as a Biomarker for Treatment in Advanced NSCLC
Not yet recruiting
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Drug: ImmunotherapyDrug: Chemotherapeutic AgentDrug: Chemotherapy
- First Posted Date
- 2022-08-04
- Last Posted Date
- 2022-08-04
- Lead Sponsor
- Fuzhou General Hospital
- Target Recruit Count
- 500
- Registration Number
- NCT05486988
- Locations
- 🇨🇳
900TH Hospital of Joint Logisti'cs Support Force, Fuzhou, Fujian, China
© Copyright 2025. All Rights Reserved by MedPath